The four-protein panel also demonstrated better sensitivity (median of 76%), specificity (median of 98%), PPV (median of 91.5%), NPV (median of 92%) and AUC (median of 93.5%) compared to CA-125 alone in distinguishing ovarian cancer from healthy controls (Wilcoxon p-values: 2.22 × 10−7, 0.02, 1.27 × 10−2, and 3.629× 10−7and and 2.34 × 10−7, respectively; Figure 1B–F). This evidence concerns the gene MUC16 and ovarian carcinoma.